<- Go Home
Tharimmune, Inc.
Tharimmune, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. It is also involved in the clinical-stage biotech research and development activities. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was founded in 2017 and is based in Red Bank, New Jersey.
Market Cap
$187.4M
Volume
2.9M
Cash and Equivalents
$7.6M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$9.08
52 Week Low
$0.95
Dividend
N/A
Price / Book Value
5.55
Price / Earnings
-1.55
Price / Tangible Book Value
5.55
Enterprise Value
$180.0M
Enterprise Value / EBITDA
N/A
Operating Income
-$10.3M
Return on Equity
225.01%
Return on Assets
-99.79
Cash and Short Term Investments
$7.6M
Debt
$195.5K
Equity
$6.2M
Revenue
N/A
Unlevered FCF
-$5.4M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium